13152 related articles for article (PubMed ID: 10470221)
1. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
2. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
3. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
4. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
6. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
[TBL] [Abstract][Full Text] [Related]
7. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
8. Elevated MIA serum levels are predictors of poor prognosis after surgical resection of metastatic malignant melanoma.
Guba M; Steinbauer M; Ruhland V; Schütz A; Geissler EK; Anthuber M; Vogt T; Bosserhoff A; Jauch KW
Oncol Rep; 2002; 9(5):981-4. PubMed ID: 12168059
[TBL] [Abstract][Full Text] [Related]
9. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
10. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
11. Serum markers in skin melanoma--preliminary study.
Dumitraşcu G; Constantin C; Manda G; Hristescu S; Mărgaritescu I; Chiriţă D; Neagu M
Roum Arch Microbiol Immunol; 2009; 68(3):125-35. PubMed ID: 20361532
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.
Klimek VM; Williams L; Chapman PB
Cytokines Cell Mol Ther; 2002 Dec; 7(2):71-4. PubMed ID: 12607797
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
Deichmann M; Benner A; Waldmann V; Bock M; Jäckel A; Näher H
J Exp Clin Cancer Res; 2000 Sep; 19(3):301-7. PubMed ID: 11144523
[TBL] [Abstract][Full Text] [Related]
15. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
17. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers].
Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520
[No Abstract] [Full Text] [Related]
18. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy.
Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD
Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031
[TBL] [Abstract][Full Text] [Related]
19. Elevated MIA levels in the serum of pregnant women and of children.
Bosserhoff AK; Küster H; Hein R
Clin Exp Dermatol; 2004 Nov; 29(6):628-9. PubMed ID: 15550140
[TBL] [Abstract][Full Text] [Related]
20. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
